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Abstract
Background: Recently published results from a large randomized trial (Canadian Cervical Cancer
Screening Trial study group) suggest that human papillomavirus testing followed by Pap smear-
based triage for human papillomavirus positive women may be an effective way to screen women
for cervical cancer. We determined the potential cost-effectiveness of including human
papillomavirus tests for cervical cancer screening for Canada and three provinces: Alberta,
Newfoundland and Ontario.
Methods: We developed four Markov decision models using data from relevant Canadian and
provincial studies and databases. The models were used to determine the number of false positive
test results, cancers, lifetime costs and life-expectancy for 27 different screening strategies that
varied by age to begin screening (18 or 25 years), screening interval (one, two, three, or five years)
and whether the currently recommended strategy (screening every year from age 18 until 21 and
then every three years afterwards with conventional Paps) was conducted prior to age 25.
Strategies were compared using incremental cost-effectiveness ratios.
Results: Screening strategies beginning at age 18 were associated with a substantial increase in the
number of false-positive test results but only small differences in the number of cancers compared
to the same strategy conducted beginning at age 25. Strategies of human papillomavirus testing first,
followed by triage with Pap smears were associated with lower costs and greater increases in life-
expectancy than the currently recommended screening strategy in Canada.
Conclusion: A strategy of human papillomavirus testing beginning at age 25, with Pap triage for
women with positive human papillomavirus results may be more effective at reducing cervical
cancer at a lower cost than the current recommended strategy for screening in Canada.
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Background
In 2008, approximately 1,450 women were expected to be
diagnosed with cervical cancer, and 420 women were
expected to die from this disease in Canada [1]. The fact
that Pap smear-based screening is offered to women in
Canada beginning at age 18 until age 70 is attributed as
the major reason for a reduction in cervical cancer mortal-
ity of almost 50% with respect to historical levels [2].
There are, however, continuing concerns with Pap smear-
based screening, including the poor reproducibility of
results, insufficient sensitivity and, as a result, the need for
screening on a relatively frequent basis in order to achieve
acceptable program sensitivity [3]. Human papillomavi-
rus (HPV) is an established cause of cervical pre-cancer
and cancer [4,5]. Studies have shown that HPV tests are
significantly more sensitive, but less specific than Pap
smear-based tests for the detection of cervical high-grade
disease [6]. In Canada, HPV tests are currently recom-
mended only as an adjunctive test for women with atypi-
cal cells of unknown significance (ASC-US) Pap smear
results [7]. To determine whether HPV testing should be
used in primary screening, a randomized trial was recently
conducted (the Canadian Cervical Cancer Screening Trial
[CCCaST]) [8,9] The aim of this trial was to determine the
sensitivity and specificity of HPV testing either alone or in
combination with Paps, compared to Pap tests only, for
the detection of cervical intraepithelial neoplasia (CIN)
grade 2 or 3 (CIN 2+). Published results from the trial
show a significantly increased sensitivity of HPV testing
for CIN 2+ (94.6, 95% CI: 84.2 - 100) compared to Pap
tests (55.4%, 95% CI: 33.6 - 77.2), but a lower specificity
(94.1%, 95% CI: 93.4 - 94.8 and 96.8%, 95% CI: 96.3 -
97.3) [8].
In this study, we used the estimates of test accuracy from
CCCaST in conjunction with a previously published
Markov model to determine the effectiveness and cost-
effectiveness of 27 different screening strategies that
included Pap tests only, HPV tests only or both Pap and
HPV tests in combination [8,10]. Four cost-effectiveness
models (one for Canada, and three provincial models for
Alberta, Newfoundland and Ontario) were developed to
determine whether a single, national strategy could be rec-
ommended or whether there was sufficient variation at
the provincial level to consider different cervical cancer
screening strategies by province.
Methods
Overview
Markov model of cervical carcinogenesis
We used a Markov model that simulates the natural his-
tory of cervical cancer in a theoretical cohort of women to
estimate lifetime costs and life expectancy of different
screening strategies. This Markov model has previously
been described in detail [10-12]. Briefly, a population
advances from one health state to another based on pre-
defined probabilities. These health states are chosen to
reflect the progression from healthy and disease-free
through pre-cancer to cancer and death. Each year,
women can either remain in the same state, progress to a
more advanced disease state, or regress to a less severe dis-
ease state. Each year, women are also at risk of dying from
causes other than cervical cancer or having a hysterectomy
for a non-cancerous uterine condition.
Natural history
The model was calibrated to obtain an age-specific HPV
prevalence curve based on large HPV epidemiology stud-
ies conducted in different Canadian settings; this was
accomplished by varying the age-specific HPV incidence
rates [13-16]. Progression and regression rates between
the different states were from the original model by Myers
et al. [10]. Benign hysterectomy rate was estimated from
the Canadian Community Health Survey [17]. Death
from non-cervical cancer causes was estimated from the
Canadian Incidence and Mortality data set [18]. Cancer
progression rates and the probability of symptoms were
from Myers et al. [10]. Stage-specific survival probabilities
were based on United States. Surveillance Epidemiology
and End Results data from the National Cancer Institute
[19]. The same underlying natural history was assumed
for Canada as a whole and for each province.
Screening strategies
We compared 27 different screening strategies as summa-
rized in Table 1. Strategies differed by the age at which to
begin screening (either age 18 or age 25) and whether the
most widely recommended strategy for cervical cancer
screening in Canada was conducted prior to age 25 [20].
This baseline recommended strategy for Canada (screen-
ing every year from age 18 until 21 and then every three
years afterwards until age 70 with conventional Pap tests)
is hereinafter designated the 'Miller' strategy. The choice
of age 25 was based on the fact that HPV testing prior to
that age suffers from an unacceptably low specificity (to
detect high grade cervical lesions) as a consequence of the
high HPV prevalence following the first few years after the
onset of sexual activity. This age may be an appropriate
age to implement HPV DNA testing because HPV infec-
tions among such women are more likely to reflect under-
lying lesions [14]. In addition to single test (HPV or Pap)
strategies, we examined a combined test strategy (HPV
and Pap), in which women who were HPV positive or
who had smears with findings of atypical squamous cells
of undetermined significance (ASC-US) or more severe (≥
ASC-US) abnormalities were referred to colposcopy. We
also examined two triage strategies: 1) HPV followed by
Pap testing for HPV positive women and 2) Pap followed
by HPV testing for women with ≥ ASC-US Pap test results.BMC Medicine 2009, 7:69 http://www.biomedcentral.com/1741-7015/7/69
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Adherence to screening recommendations by age was var-
ied based on province-specific estimates provided by the
1998 Surveillance Report on Cervical Cancer Screening in
Canada [2]. All women who received an initial screening
test were also assumed to receive the triage test if a triage
test was included as part of the strategy. Women with his-
tologically confirmed CIN of grade 1 (CIN 1) were
assumed to be followed with repeat Pap tests and to be
treated if they had another abnormal test result (≥ ASC-
US). Women with biopsy-confirmed CIN of grades 2 or 3
(CIN 2+) were assumed to receive loop electrosurgical
excision procedure (LEEP). Adherence to follow-up and
treatment was assumed to be 100%. Women with cancer
were assumed to receive stage-specific treatment. Selected
parameters used in the model are presented in Table 2.
Screening test(s) sensitivity and specificity
Estimates of sensitivity and specificity were from a
recently published randomized trial comparing HPV and
conventional Pap tests [8,9]. Since the trial enrolled
women aged 30+, we used estimates from another study
that corrected for verification bias and provided estimates
of test accuracy stratified by age <30 or 30+ to determine
the sensitivity and specificity in women aged <30 years
[21] Given a move towards considering CIN 2-3 as the dis-
ease state that is more likely to be a cancer precursor, and
CIN 1 as a marker of HPV infection, we examined two dif-
ferent thresholds for disease: CIN 1+ and CIN 2+ [22].
Conventional Pap smears were assumed for the base case
analysis; in sensitivity analyses we assumed that liquid-
based Paps would have approximately the same sensitiv-
ity and lower specificity compared to conventional Paps,
based on the results of a randomized controlled trial [23].
We did not model the impact of either type of Pap smear
on inadequate results. To address concerns that the esti-
mates of sensitivity for CIN 2+ for both Pap and HPV
reported in CCCaST may be lower than those based on
actual practice patterns in Canada, in sensitivity analyses,
we examined the impact of using more commonly
accepted estimates of sensitivity of Pap and HPV tests for
detection of CIN 2+: 55.6% and 95% respectively [24,25].
Costs
The costs (Table 2) for Pap and HPV tests including labo-
ratory costs were obtained from provincial fee schedules
and communications with selected laboratories [26-28].
Professional costs for diagnostic procedures were also
obtained from provincial fee schedules, while technical
Table 1: Twenty-seven screening test strategies that differ by age of first screening, type of screening test and frequency of screening.
Test or test 
combination
Strategy Frequency (years) Age when screening strategy begins
18 years 25 years 18-24 via Miller1, 25+ 
via strategy
Pap only Pap1 1 (age 18 to 20) and 3 
(age 21+)
X (Screening Strategy 
(SS) 1)
Pap 1 X (SS 2)
Pap 2 X (SS 3)
HPV testing only2 HPV 3 X (SS 4) X (SS 5) X (SS 6)
HPV 5 X (SS 7) X (SS 9) X (SS 9)
Co-testing3 Pap + HPV 2 X (SS 10) X (SS 11) X (SS 12)
Pap + HPV 3 X (SS 13) X (SS 14) X (SS 15)
Pap + HPV 5 X (SS 16) X (SS 17) X (SS 18)
Triage (Pap followed by 
HPV)4
Pap with HPV triage 1 X (SS 19) X (SS 20) X (SS 21)
Triage (HPV followed by 
Pap)5
HPV with Pap triage 3 X (SS 22) X (SS 23) X (SS 24)
HPV with Pap triage 5 X (SS 25) X (SS 26) X (SS 27)
1 This is the current recommendation for screening in Canada[20] Women are screened annually from age 18 to 20, and then every three years (for 
age 21+). Women who have an ≥ LSIL test result are referred for colposcopy and biopsy. Women with an ASC-US Pap result have a repeat Pap 
test and are referred to colposcopy and biopsy if their test result shows ≥ ASC-US. Women with a normal Pap test result return to routine 
screening. This strategy is referred to as the Miller strategy.
2 Women who are HPV+ (using a 1 RLU cutpoint) are referred directly for colposcopy and biopsy. Women who are HPV- return to routine 
screening.
3 Women who are HPV+ or who have an ≥ ASC-US Pap result are referred directly for colposcopy and biopsy. Women who are HPV- and have a 
normal Pap test result return to routine screening.
4 Women with an ≥ ASC-US Pap result are assumed to have an HPV test. Women who are HPV+ are referred for colposcopy. Women who have 
discordant results receive repeat testing with an HPV test and are referred to colposcopy if they are HPV+. Women who have an initial or 
subsequent normal test result are assumed to return to routine screening.
5 Women who are HPV+ are assumed to have a Pap test. Women with an ≥ ASC-US Pap result are referred for colposcopy. Women with 
discordant test results are assumed to receive another HPV test and are referred to colposcopy if they are HPV+. Women with an initial or 
subsequent normal test result are assumed to return to routine screening.BMC Medicine 2009, 7:69 http://www.biomedcentral.com/1741-7015/7/69
Page 4 of 11
(page number not for citation purposes)
costs were based on data from the Ontario Case Costing
Initiative website [26-29]. These were then adjusted for
Alberta and Newfoundland by using provincial costs per
weighted case (CPWC) as reported by the Canadian Insti-
tute of Health Information (CIHI) [30]. Costs for cancer
care by stage were based on figures from Brisson et al.
(2007), and were also adjusted for each province using
CIHI's CPWCs [31]. Costs from Ontario were assumed to
reflect those for the country as a whole. All estimates were
measured in 2006 Canadian dollars. The triage test strate-
gies were assumed to be conducted at two separate visits.
Both tests were assumed to be collected at a single visit for
the combined test procedure.
Utilities
For the model, previously published utility estimates for a
false positive Pap screening test result and cancer (Stage I,
Stage II-IV) were used (Table 2); these estimates were
assumed to be constant by age [32]. The false-positive test
result was assumed to be applicable to both Pap and HPV
tests. Since these estimates were derived from a small
study of college-aged women in the U.S., we examined the
impact of quality-adjusted life years on cost-effectiveness
results in sensitivity analyses only.
Analysis
The analysis was conducted from a health-system perspec-
tive. We calculated incremental cost-effectiveness ratios
(ICERs) in which the average lifetime costs and life-
expectancy or quality-adjusted life-expectancy of a strat-
egy were compared with an adjacent strategy. Strategies
that were more costly and less effective or less costly and
less cost-effective than an adjacent strategy were consid-
ered to be dominated. We adjusted future costs and life
expectancy to current values by discounting them at 3%
annually. In sensitivity analyses, we calculated cost per
quality-adjusted life year. In addition to one-way sensitiv-
ity analyses, in which key parameters, including test accu-
racy estimates, adherence to screening and costs were
varied, a probabilistic sensitivity analysis was also per-
Table 2: Selected estimates for screening test accuracy, costs and utilities.
Screening Adherence (1)
<20 0.5-0.75 (0.35-1.0)
20-29 0.5-0.8 (0.35-1.0)
30-39 0.7-0.9 (0.5-1.0)
40-49 0.6-0.9 (0.4-1.0)
50+ 0.3-1.0 (0.2-1.0)
Screening Test Accuracy [8,21]1,2
Age <30 Age 30+
Pap sensitivity for CIN 1+ 0.42 (0.31-0.72) 0.32 (0.30-0.66)
Pap specificity for <CIN 1 0.98 (0.80-0.95) 0.94 (0.82-0.95)
HPV sensitivity for CIN 1+ 0.83 (0.68-1.0) 0.71 (0.65-1.0)
HPV specificity for <CIN 1 0.83 (0.80-0.97) 0.97 (0.94-1.0)
HPV and Pap sensitivity for CIN 1+ 0.88 (0.72-1.0) 0.75 (0.69-1.0)
HPV and Pap specificity for <CIN 1 0.82 (0.79-0.96) 0.95 (0.92-1.0)
Costs in Canadian $ (2006)[26-29,31]3
Canada and Ontario Alberta Newfoundland
Conventional Pap $28 ($14-$56) $30 ($15-$59) $29 ($14-$58)
Liquid-based Pap $32 ($16-64) $35($17-$70) $33 ($16-$65)
HPV test (hc2) $53 ($14-$106) $50 ($14-$100) $53 ($14-$106)
Colposcopy + biopsy $337 ($168-$673) $376 ($188-$752) $412 ($206-$824)
LEEP $965 ($83-$1930) $1082 ($541-$2164) $1044 ($522-$2088)
Stage I Cancer $11153 ($5576-$22305) $12126 ($6063-$24253) $11898 ($5949-$23797)
Stage II - III Cancer $17644 ($8822-$35288) $19185 ($9592-$38369) $18824 ($9412-$37648)
Stage IV - Cancer $24110 ($12055-$48220) $26215 ($13107-$52430) $25722 ($21861-$51445)
Utilities[32]4
False-positive screening test result -.02
Duration 2 1/2 months[8]
Stage I Cancer 0.76
Duration 5 years 5
Stage II - IV Cancer 0.67
Duration 5 years 5
1 Ranges used for beta distributions for probabilistic sensitivity analyses
2 Estimates of sensitivity assumed to be the same for LBC; specificity estimated to be 0.84[23] of base estimate of specificity for conventional Pap.
3 Ranges used for normal distributions for costs for probabilistic sensitivity analyses
4 Cost per quality-adjusted life-year calculated in sensitivity analyses
5 Women who are alive at the end of 5 years are assumed to enter the cancer survivor state. The utility for a cancer survivor is assumed to be 1.BMC Medicine 2009, 7:69 http://www.biomedcentral.com/1741-7015/7/69
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formed on strategies consistently identified as cost-effec-
tive to explore the impact of the joint uncertainty
surrounding model parameters. This analysis was under-
taken by assigning probability distributions to key model
parameters (costs and estimates of sensitivity and specifi-
city) and subsequently propagating this uncertainty
through the model using Monte Carlo sampling tech-
niques to produce information on the likelihood that
each intervention produces the greatest amount of net
benefit at different willingness to pay thresholds. The
results of these simulations are presented as cost-effective-
ness acceptability curves (CEACs).
Results
Model calibration
Figure (1a - d) presents the model predicted and observed
age-specific cancer incidence rates. All provinces show a
similar pattern of a steadily increasing incidence, with a
peak in the mid-40s and a leveling off or fluctuations in
incidence occurring after that. Of the three provinces,
Newfoundland has the highest observed cancer incidence.
Base case results
Table 3 presents the expected lifetime number of false
positives and cancers per 100,000 women associated with
the different screening strategies (for Ontario; results were
similar for the other provinces and Canada as a whole).
Strategies identified as cost-effective are presented in bold.
As shown, the Miller strategy was associated with the high-
est expected number of cancers. Strategies of HPV testing
followed by Pap triage were associated with fewer false-
positive results and fewer cancers compared to strategies
that used the Miller recommendations prior to age 25,
and then switched to another strategy, or HPV-only strat-
egies (conducted at less frequent screening intervals). Of
note, strategies conducted beginning at age 18 were asso-
ciated with a much higher number of false-positives, but
slightly fewer cancers compared to the same strategies
starting at age 25.
Figures 2 and 3 present the efficiency curves for the three
different Provincial models and the Canada model. The
strategies identified as cost-effective were similar for the
Model estimated and observed age-specific cancer incidence curves for Canada and three provinces: Alberta, Ontario and  Newfoundland Figure 1
Model estimated and observed age-specific cancer incidence curves for Canada and three provinces: Alberta, 
Ontario and Newfoundland.
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four models. HPV with Pap triage conducted every three
or five years was associated with ICERs <$50,000 per life
year gained. Pap followed by HPV triage was also associ-
ated with ICERs that were <$100,000 per life year gained.
Of note, the currently recommended strategy of screening
yearly beginning at age 18 and then every three years from
age 21 (Miller strategy) was consistently more costly and
less effective (dominated) than a strategy of HPV with Pap
triage, beginning at age 25 and conducted every three
years.
Sensitivity analyses
Results were similar to those obtained for the base case
when adherence to screening was varied, liquid-based
cytology was assumed instead of conventional Paps, HPV
triage was assumed for women who had ASC-US Pap
results instead of repeat Pap smears, costs for HPV DNA
testing, colposcopy and biopsy or treatment for CIN or
cancer were varied over a wide range or the outcome was
cost per quality-adjusted life year instead of cost per life
year. Results were also similar to those obtained for the
base case for a range of estimates of sensitivity and specif-
icity including the use of more commonly observed esti-
mates of sensitivity for conventional Paps and HPV for
detection of CIN 2+. The results were sensitive to the
choice of discount rate, with HPV with Pap triage, begin-
ning at age 25 conducted every five years dominating the
Miller strategy when the discount rate was low (approxi-
mately <2.0%); at higher rates, the same strategy was iden-
tified as cost-effective compared to the Miller strategy,
although it should be noted that the differences in life-
expectancy were small (<1/2 day). If the cost of the Pap
was reduced by half to approximately $14, the Miller strat-
egy was the cheapest option; screening strategies using
Pap with HPV triage conducted every year beginning at
age 25 or age 18 were associated with ICERs of less than
$100,000 per LY.
The results of the probabilistic sensitivity analysis are pre-
sented in Figure 4 (for Ontario) in the form of cost-effec-
tiveness acceptability curves. The frontier is formed by
selecting only those strategies that have the greatest net
benefits per willingness to pay threshold. As shown, if a
decision maker is willing to pay between $20,000 and
$50,000 per LY, a strategy of HPV testing followed by Pap
triage for HPV positive women, conducted every three
years, beginning at age 25 would provide the greatest net
benefit. If willingness to pay is below $20,000 per LY, the
Table 3: Model predicted cancer (all stages) and false positive test results per 100,000 (Ontario).
Strategy False Positives Cancer (All Stages)
No Intervention (Natural history) 1 -2 , 1 4 5
HPV with Pap Triage, q5, age 251(SS 26) 2,871 736
HPV with Pap Triage, q3, age 251(SS 23) 5,585 467
HPV with Pap Triage, q5, age 18 (SS 25) 7,044 679
HPV with Pap Triage, q3, age 181 (SS 22) 9,872 437
Miller at age 18, then HPV with Pap Triage, q5, age 25 (SS 27) 11,404 658
Miller at age 18, then HPV with Pap Triage, q3, age 25 (SS 24) 14,160 411
Miller strategy (Pap q1 beginning at age 18, then q3 at age 21) (SS 1) 20,529 809
HPV only, q5, age 25 (SS 8) 22,437 586
Pap only, q2, age 18 (SS 3) 25,103 600
Pap with HPV Triage, q1, age 25 (SS 20) 27,660 364
Pap and HPV, q5, age 25 (SS 17) 30,817 548
Miller at age 18, then Pap with HPV Triage, q1, age 251(SS 21) 37,034 330
HPV only, q3, age 25 (SS 5) 40,789 361
HPV only, q5, age 18 (SS 7) 40,957 538
Pap with HPV Triage, q1, age 181(SS 19) 44,903 309
Pap only, q1, age 181(SS 2) 46,337 303
Pap and HPV, q5, age 18 (SS16) 50,790 500
Pap and HPV, q3, age 25 (SS 14) 54,835 335
HPV only, q3, age 18 (SS 4) 60,456 330
Miller at age 18, then HPV only, q5, age 25 (SS 9) 61,375 517
Miller at age 18, then Pap and HPV, q5, age 25 (SS 18) 73,470 481
Pap and HPV, q3, age 18 (SS 13) 76,438 304
Miller at age 18, then HPV only, q3, age 25 (SS 6) 79,887 301
Pap and HPV, q2, age 25 (SS 11) 82,340 229
Miller at age 18, then Pap and HPV, q3, age 25 (SS 15) 97,645 283
Pap and HPV, q2, age 181(SS 10) 118,646 180
Miller at age 18, then Pap and HPV, q2, age 252 (SS 12) 125,229 184
1 Strategy falls on the efficiency frontier (for Ontario)BMC Medicine 2009, 7:69 http://www.biomedcentral.com/1741-7015/7/69
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Efficiency curves for Canada and the province of Alberta Figure 2
Efficiency curves for Canada and the province of Alberta.
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Efficiency curves for the provinces of Ontario and Newfoundland Figure 3
Efficiency curves for the provinces of Ontario and Newfoundland.
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same strategy of HPV with Pap triage conducted every five
years is identified as providing the greatest net benefit.
Discussion
Our findings suggest that a strategy of screening every
three years, beginning at age 25, with HPV testing first fol-
lowed by Pap triage for women with positive HPV results,
and referral to colposcopy for any woman with an ≥ ASC-
US Pap result may be more effective at preventing cancer,
and less costly than the currently recommended strategy
of screening every year beginning at age 18 and then every
three years at age 21 with referral to colposcopy for any
woman with an ≥ low grade squamous intra-epithelial
lesion Pap result, and repeat testing for women with ASC-
US Pap results. These findings were consistent at both the
Provincial level and for Canada as a whole.
These findings reflect those of Mayrand et al. 2007, who
showed that a strategy of HPV testing followed by Pap
triage would be more sensitive and as specific as a strategy
of sending everyone to colposcopy with a test result of ≥
LSIL, but less sensitive and more specific than a strategy of
sending everyone with an ≥ ASC-US test result to colpos-
copy [8,9]. This is because the currently recommended
strategy for screening in Canada is a hybrid: women with
ASC-US Pap test results have repeat exams instead of
being sent immediately to colposcopy; women with ≥
LSIL are referred for immediate colposcopy. The strategy
of HPV testing followed by Pap triage was more effective
because all women with a positive test result for both were
sent to colposcopy, and women with a negative HPV test
result were assumed to return to routine screening. We
assumed that women with discordant results would
receive a repeat HPV test and be referred for colposcopy if
positive, or return to routine screening if negative. This
strategy thus avoids the increased costs of screening
women at an early age, but increases the likelihood of
detecting significant disease by using HPV testing first, fol-
lowed by Pap testing. Our findings are similar to those of
Goldhaber-Fiebert et al. (2008) who showed that in the
US, triennial Pap-based screening with HPV triage, begin-
ning at age 21, with a switch to HPV testing with Pap
triage at age 30 years was cost-effective [33].
Acceptability curves for strategies identified as cost effective (for Ontario - results for other provinces and Canada are similar) Figure 4
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There are limitations to this analysis. The first is the lack
of data from a single Canadian study that provides esti-
mates of HPV and Pap screening test performance by age
(<30, 30+). To address this we used data from other stud-
ies that corrected for verification bias [3,21]. Our findings
were robust across a range of estimates for sensitivity and
specificity. Another potential limitation of this analysis is
that the differences in cancer incidence between the prov-
inces may be due to other differences besides adherence;
however to our knowledge, there are no published studies
that have explored the basis for provincial differences [2].
Finally, we did not include vaccination in our analysis.
The analysis by Goldhaber-Feibert et al. also examined
screening in combination with HPV vaccination; they
concluded that for a cohort of vaccinated girls, a strategy
of Pap-based screening with HPV triage beginning at age
25 with a switch to HPV with Pap triage at age 35 con-
ducted either every three or every five years may be cost-
effective [33]. However, given the lack of long-term data
on the performance of Pap and HPV-based cervical cancer
screening in the era of vaccination, and different decisions
at the Provincial level regarding the schedule for dosing
for HPV vaccination, it is currently unclear what changes
will be needed, if any [34]. In terms of expected technical
performance, strategies based on HPV testing with Pap
triage may be more likely to suit cervical cancer screening
needs post-vaccination [35].
Conclusion
In conclusion, our results suggest that a new approach to
screening that combines HPV testing with triage using Pap
smears, conducted every three years, beginning at age 25
may be associated with fewer cancers and lower costs than
the currently recommended strategy of screening every
year from age 18 to age 21, and then every three years with
cytology only.
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